As a world-leading service provider of antibody development and generation, Creative Biolabs is ready to provide a whole series of biomarker-specific in vitro diagnostic (IVD) antibody development services. A team of experienced scientists focused on antibody development are pleased to assist you in your project in a timely and cost-effective manner. Here, we introduce our IVD antibody development services targeting elastase-α1-antitrypsin.
General Introduction: Elastase-α1-antitrypsin
Alpha-1-antitrypsin (AAT), referred to alpha-1 proteinase inhibitor or alpha-1 protease inhibitor, is a protein belonging to the serine protease inhibitor (serpin) superfamily. AAT in humans, a 52-kDa glycoprotein, is produced mainly by hepatocytes and encoded by the SERPINA1 gene. Based on the capability of inhibiting the serine protease, neutrophil elastase, AAT is regarded as the primary anti-elastase of the lower respiratory tract. Additionally, AAT enables to modulate both inflammation and apoptosis. A mutant form of AAT plays a role in disease pathogenesis, including the misfolding of AAT protein, accumulation of misfolded protein polymers. Neutrophil elastase and alpha 1-antitrypsin are a pair of protease and protease inhibitor counterparts. The imbalance between the two counterparts is generally thought to cause tissue damage. A deficiency in alpha1-antitrypsin is associated with a variety of disease including liver cancer, bladder cancer, gallbladder cancer, malignant lymphoma, and lung cancer.
Fig. 1 Alpha-1 Antitrypsin Deficiency.
Elastase-α1-antitrypsin as A Candidate Marker for Sepsis
Sepsis can be caused by severe bacterial infection. Human α1-antitrypsin (hAAT) acts as an anti-inflammatory, immune-modulating, and tissue-protective circulating serine-protease inhibitor, along with increasing levels during acute-phase responses. Related report has been shown that hAAT reduces the bacterial burden after infection. Additionally, hAAT treatment may be considered a preemptive therapeutic measure for individuals who are at risk for bacterial infections. hAAT significantly reduced infection-induced leukopenia and liver, pancreas, and lung injury. Alpha-1 antitrypsin peptide has been discovered as a novel sepsis biomarker with immunomodulatory function.
IVD Antibody Development Services for Elastase-α1-antitrypsin
Antibodies are key elements for antibody-based immunoassays for detecting and quantifying antigens of interest in biological samples such as the blood, urine, and tissue preparations. With years of devotion to antibody discovery, Creative Biolabs has built a versatile IVD platform to provide custom biomarker-specific IVD antibody development services to global clients. Besides antibody generation, we also provide one-stop diagnostic immunoassay development services.
We offer custom-built IVD antibody development services to suit the exact requirements of our clients. Please do not hesitate to contact us for more details.
Reference
For Research Use Only.
